CACNA1D and Parkinson disease: Recent meta-analyses have concluded that the use of calcium-channel blockers can reduce the risk of developing Parkinson’s disease by up to 30% (Lang et al., 2015), and blockers of CaV1.3 for treating Parkinson’s by reducing mitochondrial impairment and neuroinflammation are currently in Phase III clinical trials (Swart and Hurley, 2016).